Cooley and Davis Polk advise Revance Therapeutics on $135 million public offering
Cooley advised Newark-based biopharmaceutical company Revance Therapeutics Inc. in raising $134.6 million in its public offering which closed Nov. 9. The company sold 3,737,500 shares of common stock at a price of $36 per share. The share volume includes the additional allotment of 487,500 shares purchased by the underwriters. Revance develops products used for aesthetic purposes, like treatment for wrinkles, excessive sweating and frown lines.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
